869782-94-5

Basic information

• Product Name: 5-TRIFLUOROMETHOXY-1H-INDAZOLE-3-CARBOXYLIC ACID
• Synonyms: 5-TRIFLUOROMETHOXY-1H-INDAZOLE-3-CARBOXYLIC ACID;5-TRIFLUOROMETHOXYL-3-INDAZOLE-CARBOXYLIC ACID;5-(Trifluoromethoxy)-1H-indazole-3-carboxylic acidcarboxylic acid;1H-Indazole-3-carboxylicacid, 5-(trifluoroMethoxy)-
• CAS NO: 869782-94-5
• Molecular Formula: C9H5F3N2O3
• Molecular Weight: 246.14
• Product Categories: Indazoles
• Mol File: 869782-94-5.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-TRIFLUOROMETHOXY-1H-INDAZOLE-3-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 5-TRIFLUOROMETHOXY-1H-INDAZOLE-3-CARBOXYLIC ACID(869782-94-5)
• EPA Substance Registry System: 5-TRIFLUOROMETHOXY-1H-INDAZOLE-3-CARBOXYLIC ACID(869782-94-5)

Safety Data

• Hazardous Substances Data: 869782-94-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Development:
5-TRIFLUOROMETHOXY-1H-INDAZOLE-3-CARBOXYLIC ACID is used as a chemical intermediate for the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Development:
In the agrochemical industry, 5-TRIFLUOROMETHOXY-1H-INDAZOLE-3-CARBOXYLIC ACID is used as a precursor in the synthesis of agrochemicals, such as pesticides and herbicides, due to its potential to enhance the effectiveness of these products.
Used in Organic Synthesis:
5-TRIFLUOROMETHOXY-1H-INDAZOLE-3-CARBOXYLIC ACID is used as a building block in organic synthesis for the production of other chemical compounds. Its versatile structure makes it a valuable component in the creation of novel molecules with specific properties and applications.
Note: The specific applications and reasons for using 5-TRIFLUOROMETHOXY-1H-INDAZOLE-3-CARBOXYLIC ACID in different industries would need to be further investigated and researched, as the provided materials do not detail specific uses beyond its potential in medicinal chemistry, agrochemicals, and organic synthesis.

Upstream product

• 169037-23-4 5-trifluoromethoxy-1H-indole-2,3-dione 
• 1221150-40-8 N-amino-3,3-diethoxy-5-trifluoromethoxyisatin 

Downstream Products

• 932041-12-8 methyl 5-(trifluoromethoxy)-1H-indazole-3-carboxylate 

Relevant articles and documents

ANTICANCER AGENT

An anticancer agent comprising a compound represented by the formula (I) [R1 represents hydrogen atom, hydroxyl group, a C1-6alkoxy group and the like; R2 and R3 represents hydrogen atom, a halogen atom, a C1-6alkyl group and the like; R4 represents hydrogen atom, a C1-6alkyl group, a C1-6alkylsulfonyl group and the like; R5 represents hydrogen atom or a substituent; .... represents a single bond or a double bond; R6 and R7 represents hydrogen atom, a C1-6alkyl group and the like; R8 represents hydrogen atom, a C1-6alkyl group and the like; A represents -O-, -S-, or - CH2-; D represents -C= or -N=; X represents methylene group, -O-, or -CO-; Q represents -N= or -C(R8)=; and Y represents a heterocyclic group or amino group], which shows a superior inhibitory activity against pim-1 kinase.

Optimization of N-benzoylindazole derivatives as inhibitors of human neutrophil elastase

Human neutrophil elastase (HNE) is an important therapeutic target for treatment of pulmonary diseases. Previously, we identified novel N-benzoylindazole derivatives as potent, competitive, and pseudoirreversible HNE inhibitors. Here, we report further development of these inhibitors with improved potency, protease selectivity, and stability compared to our previous leads. Introduction of a variety of substituents at position 5 of the indazole resulted in the potent inhibitor 20f (IC50 ～10 nM) and modifications at position 3 resulted the most potent compound in this series, the 3-CN derivative 5b (IC50 = 7 nM); both derivatives demonstrated good stability and specificity for HNE versus other serine proteases. Molecular docking of selected N-benzoylindazoles into the HNE binding domain suggested that inhibitory activity depended on geometry of the ligand-enzyme complexes. Indeed, the ability of a ligand to form a Michaelis complex and favorable conditions for proton transfer between Hys57, Asp102, and Ser195 both affected activity.

DIAZONIUM-FREE METHOD TO MAKE AN INDAZOLE INTERMEDIATE IN THE SYNTHESIS OF BICYCLIC 5-(TRIFLUORMETHOXY)-1H-3-INDAZOLECARBOXYLIC ACID AMIDES

The present invention provides novel methods for preparing 5-(trifluoromethoxy)-lH-3- indazolecarboxylic acid (3), which is a useful precursor for the preparation of bicyclic-5- trifluoromethoxy-lH-indazole-S-carboxylic acid amides of Formula (1).Compounds of Formula (1) are active as agonists and partial agonists of the nicotinic alpha-7 receptor and are being studied for their use in the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain, such as for the treatment of Alzheimer's disease and schizophrenia, as well as other psychiatric and neurological disorders.The present methods are useful for preparing compound (3) on scale up levels

NICOTINIC ALPHA-7 RECEPTOR LIGANDS AND PREPARATION AND USES THEREOF

The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds which act as ligands for the α7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof

The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands for the α7 nACh receptor subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.